메인으로

Targeted Therapy for NSCLC (OBX02-011)

ONCOBIX's research is committed to bringing better progress.

  • home icon

PIPELINE

Developing 4th-Generation Targeted Therapy for Lung Cancer

ONCOBIX is developing the 4th-generation of targeted lung cancer drugs for which there is currently no standardized treatment.

Targeted EGFR Gene Mutation

  • - Among the major causes of NSCLC, EGFR mutation accounts for approximately 10-30% of the cases, highlighting the urgent need for treatment.

Overcoming Resistance to 3rd-generation Drugs

  • - Mutations in the amino acids of EGFR proteins are one of the main causes of developing resistance to NSCLC drugs.
  • - Currently, the NSCLC treatment uses 1st to 3rd-generations of drugs depending on the mutations. However, the emerging issue of resistance to the third-generation drug Osimertinib (Tagrisso) raises the need for the development of new drugs. ONCOBIX is working on developing a 4th-generation lung cancer treatment such as OBX02-011 to overcome the resistance to the 3rd-generation drugs.

ONCOBIX is developing innovative NSCLC therapies that would overcome the resistance to the 3rd-generation lung cancer treatments and target EFGR, the known cause of lung cancer.

Main Pipelines OBX02 SERIES
  • Overcoming
    Resistance to 3rd-Generation
    Drugs
  • EGFR Mutation
  • NSCLC

회원로그인

회원가입